Project OPTIMAB – Entwicklung eines mehrfach-optimierten bispezifischen PSMAxCD3 Antikörpers zur Krebstherapie

Basic data

Acronym:
OPTIMAB
Title:
Entwicklung eines mehrfach-optimierten bispezifischen PSMAxCD3 Antikörpers zur Krebstherapie
Duration:
01/01/2017 to 31/12/2019

Involved staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Internal Medicine Department II
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

Help

will be deleted permanently. This cannot be undone.